

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.usplo.gov

MAIN IN		-	www.nsp.o.gov		
	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
APPLICATION NO.		yi Li	PF116D1C1	9646	
09/923,444	08/08/2001	Vill			
22105 7	590 03/06/2003	ı			
HUMAN GENOME SCIENCES INC			EXAMINER		
9410 KEY WEST AVENUE			ALLEN, MARIANNE P		
ROCKVILLE,	MD 20850				
			ART UNIT	PAPER NUMBER	
			1631		
			DATE MAILED: 03/06/2003		
				- 1	
				1	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)				
Office Action Summary		09/923,444	LI ET AL.				
		Examiner	Art Unit				
		Marianne P. Allen	1631				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)⊠ Responsive to communication(s) filed on <u>20 December 2002</u> .							
1)⊠	•	is action is non-final.					
2a)□	,—		prosecution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-29</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
	6) Claim(s) is/are rejected.						
1	Claim(s) is/are objected to.						
8) Claim(s) 1-29 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) 🔲 Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	nary (PTO-413) Paper No(s) al Patent Application (PTO-152)				

Art Unit: 1631

DETAILED ACTION

In view of applicant's concern regarding the format of the prior restriction requirement (Paper No. 5, mailed 11/29/02), it is hereby vacated in view of the following restriction requirement. Newly presented claims 24-29 are included.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13, drawn to isolated polynucleotides and a method of producing the encoded protein, classified in class 435, subclass 69.1.
- II. Claims 14-15, 21, and 24-29, drawn to isolated polypeptides, classified in class530, subclass 350.
- III. Claim 16, drawn to an antibody, classified in at least class 530, subclass 387.1, for example.
- IV. Claim 17, drawn to antagonist/inhibitors of a polypeptide, classified in at least class 530, subclass 324, for example.
- V. Claim 18, drawn to an agonist of polypeptide, classified in at least class 530, subclass 24, for example.
- VI. Claim 19, drawn to a method of treating with an agonist, classified in class 514, subclass 12.
- VII. Claim 20, drawn to a method of treating with an antagonist, classified in class 514, subclass 12.
- VIII. Claim 22, drawn to a method of gene therapy, classified in class 514, subclass 44.
- IX. Claim 23, drawn to methods of screening, classified in class 435, subclass 7.1.

Application/Control Number: 09/923,444

Art Unit: 1631

The inventions are distinct, each from the other because of the following reasons:

The products of groups I-V are structurally distinct polynucleotides, polypeptides, agonists, antibodies, and antagonists/inhibitors and would require non-coextensive literature searches. The methods of groups VI -IX are distinct, each from the other, because they have different method steps, starting materials, and/or goals. They would require non-coextensive literature searches. The products are distinct from the methods as they can be used in a variety of methods as demonstrated by the claims.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and necessity for non-coextensive literature searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne P. Allen whose telephone number is 703-308-0666. The examiner can normally be reached on Monday-Friday, 8:30 am - 2:30 pm.

Page 3 Application/Control Number: 09/923,444

Art Unit: 1631

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on 703-308-4028. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

When have the production of the producti

Primary Examiner Art Unit 1631

mpa March 5, 2003